摘要
目的探讨帕利哌酮缓释片治疗首发精神分裂症的疗效和安全性。方法 60例符合CCM D-3诊断标准的首发精神分裂症患者随机分为两组,分别予帕利哌酮缓释片(治疗组)和阿立哌唑(对照组)治疗,共8周,采用阳性症状和阴性症状量表(PAN SS)评定疗效,副作用量表(TESS)评定副反应。结果治疗8周两组疗效相当,治疗组有效率90%,对照组有效率83.3%,差异无显著性,但治疗组4周时阳性因子分即明显下降,较对照组有显著差异(t=3.99,P<0.05);治疗组8周时阴性因子分较治疗前显著下降,较对照组有显著差异(t=5.97,P<0.05)。结论帕利哌酮缓释片和阿立哌唑对首发精神分裂症疗效相当,帕利哌酮缓释片起效快,并且对阴性症状有较好的疗效,安全性高。
Objective To investigate the efficacy and safety of paliperidone in the treatment of first-episode schizophrenia.Methods A total of 60 cases met the CCMD-3 criteria for first-episode schizophrenia were divided into two groups randomly,treated with paliperidone and aripiprazole respectively for 8 weeks.The Positive and Negative Syndrome Scale（PANSS）and Treatment Emergent Symptom Scale（TESS） were used to access the therapeutic efficacy and side effects respectively.Results Paliperidone was as effective as aripiprazole for the treatment of first-episode schizophrenia（P0.05）,the effective rate was 90% in treatment group and 83.3% in control group.there was no significant difference between two groups in significant improvement rate.However,from 4 weeks positive factor points in the treatment group was decreased significantly（t=3.99,P0.05）,and negative factor points in the treatment group was decreased at 8 weeks,there was a significant difference than control group（t=5.97,P0.05）.Conclusion Paliperidone is as effective as aripiprazole in the treatment of first-episode schizophrenia.However,it has much better effect for the negative symptoms,and has higher safety.
出处
《中国健康心理学杂志》
2013年第2期185-186,共2页
China Journal of Health Psychology
